We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Coherus (CHRS), Junshi Announce Positive NSCLC Study Results
Read MoreHide Full Article
Coherus BioSciences, Inc (CHRS - Free Report) and partner Shanghai Junshi Biosciences Co., Ltd. announced positive interim results from a late-stage study evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC).
Toripalimab is an anti-PD-1 monoclonal antibody. The randomized, double-blind, placebo-controlled phase III study, “CHOICE-01”, evaluated toripalimab plus chemotherapy arm vis-à-vis placebo plus chemotherapy arm.
A total of 465 treatment-naive advanced NSCLC patients (220 squamous and 245 non-squamous) were randomized in the ratio of 2:1.
The interim results showed that toripalimab plus chemotherapy met primary endpoint with significant improvement in progression free survival (PFS) compared to chemotherapy alone. The 1-year PFS rates for toripalimab and placebo arms were 32.6% and 13.1%, respectively. This improvement in PFS was observed in both squamous and non-squamous NSCLC and regardless of PD-L1 expression.
Data support the use of toripalimab with chemotherapy as first-line therapy for patients with NSCLC. Toripalimab in combination with chemotherapy, compared with chemotherapy alone, resulted in better objective response rate (ORR) and median duration of response (DoR).
Overall survival data were not yet mature as of Mar 7, 2021.
The candidate is also being evaluated in late-stage studies in esophageal, lung, liver, breast, kidney, bladder, stomach, and skin cancers.
Shares of Coherus have declined 12% in the year so far compared with the industry’s 0.2% decline.
Image Source: Zacks Investment Research
A rolling submission of the first toripalimab Biologics License Application (BLA) is underway in the United States for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). The FDA has granted Breakthrough Therapy designation to toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC and also for toripalimab monotherapy in second or third line treatment of recurrent or metastatic NPC.
Toripalimab was the first domestic anti-PD-1 monoclonal antibody approved in China as Tuoyi.
While the NSCLC markets represent potential, competition is stiff from bigwigs like Merck’s (MRK - Free Report) Keytruda, Roche’s (RHHBY - Free Report) Tecentriq and Bristol Myers’ (BMY - Free Report) Opdivo.
Image: Bigstock
Coherus (CHRS), Junshi Announce Positive NSCLC Study Results
Coherus BioSciences, Inc (CHRS - Free Report) and partner Shanghai Junshi Biosciences Co., Ltd. announced positive interim results from a late-stage study evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC).
Toripalimab is an anti-PD-1 monoclonal antibody. The randomized, double-blind, placebo-controlled phase III study, “CHOICE-01”, evaluated toripalimab plus chemotherapy arm vis-à-vis placebo plus chemotherapy arm.
A total of 465 treatment-naive advanced NSCLC patients (220 squamous and 245 non-squamous) were randomized in the ratio of 2:1.
The interim results showed that toripalimab plus chemotherapy met primary endpoint with significant improvement in progression free survival (PFS) compared to chemotherapy alone. The 1-year PFS rates for toripalimab and placebo arms were 32.6% and 13.1%, respectively. This improvement in PFS was observed in both squamous and non-squamous NSCLC and regardless of PD-L1 expression.
Data support the use of toripalimab with chemotherapy as first-line therapy for patients with NSCLC. Toripalimab in combination with chemotherapy, compared with chemotherapy alone, resulted in better objective response rate (ORR) and median duration of response (DoR).
Overall survival data were not yet mature as of Mar 7, 2021.
The candidate is also being evaluated in late-stage studies in esophageal, lung, liver, breast, kidney, bladder, stomach, and skin cancers.
Shares of Coherus have declined 12% in the year so far compared with the industry’s 0.2% decline.
Image Source: Zacks Investment Research
A rolling submission of the first toripalimab Biologics License Application (BLA) is underway in the United States for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). The FDA has granted Breakthrough Therapy designation to toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC and also for toripalimab monotherapy in second or third line treatment of recurrent or metastatic NPC.
Toripalimab was the first domestic anti-PD-1 monoclonal antibody approved in China as Tuoyi.
While the NSCLC markets represent potential, competition is stiff from bigwigs like Merck’s (MRK - Free Report) Keytruda, Roche’s (RHHBY - Free Report) Tecentriq and Bristol Myers’ (BMY - Free Report) Opdivo.
Coherus currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here